Skip to content
The Nexus
DossierENTITY

Luke Miels

Coverage of Luke Miels in the Nexus archive.

Earliest in view: Apr 12 · 15:02 UTCMost recent: Jun 9 · 07:28 UTC
Co-mentioned in this coverage
GSKorganization3Nuvalentorganization2oncologytopic2lung cancertopic2Bostonplace2cancer treatmenttopic1Mo-Reztopic1Ovarian cancertopic1Endometrial cancertopic1
Recent coverage
  • BUSINESSJun 9 · 07:28 UTCGUARDIAN US
    GSK to buy US cancer treatment firm Nuvalent for $10.6bn

    British drugmaker GSK, led by new CEO Luke Miels, has agreed to acquire US-based cancer treatment firm Nuvalent for $10.6 billion. The deal aims to strengthen GSK's oncology portfolio, with Nuvalent developing three late-stage lung cancer medications.

  • BUSINESSJun 9 · 07:28 UTCTHE GUARDIAN WORLD
    GSK to buy US cancer treatment firm Nuvalent for $10.6bn

    British drugmaker GSK has agreed to acquire US-based cancer treatment company Nuvalent for $10.6 billion to expand its oncology portfolio. The deal includes Nuvalent's three late-stage lung cancer medications.

  • HEALTHApr 12 · 15:02 UTCTHE GUARDIAN WORLD
    GSK reports promising early results in ovarian and womb cancer drug trial

    GSK reported early trial results showing Mo-Rez reduced or eliminated tumors in 62% of ovarian cancer patients and 67% of endometrial cancer patients. The CEO, Luke Miels, is advancing drug development efforts for the potential blockbuster treatment.